tailieunhanh - Báo cáo y học: "Focusing on diffuse (interstitial) lung disease: a rapidly evolving field"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài: "Focusing on diffuse (interstitial) lung disease: a rapidly evolving field. | Available online http content 3 1 16 Review Focusing on diffuse interstitial lung disease a rapidly evolving field Roland M du Bois Royal Brompton Hospital London UK Correspondence Roland M du Bois Royal Brompton Hospital Sydney Street London SW3 6NP UK. Tel 44 20 7351 8327 fax 44 20 7351 8336 e-mail Received 14 January 2002 Accepted 15 January 2002 Published 19 February 2002 Respir Res 2002 3 16 2002 BioMed Central Ltd Print ISSN 1465-9921 Online ISSN 1465-993X The diffuse interstitial lung diseases have attracted an unprecedented level of interest over the past 5 years. Statements from the American Thoracic Society European Respiratory Society committees on idiopathic pulmonary fibrosis IPF sarcoidosis and the idiopathic interstitial pneumonias and from the British Thoracic Society on diffuse parenchymal lung diseases 1-3 have defined the phenotype of the idiopathic interstitial pneumonias more tightly than was previously the case. Much of the credit for this lies in the exploitation of high-resolution computed tomography to provide a three-dimensional anatomical display with great precision of the patterns of abnormality that occur in diffuse lung diseases 4 . Such precision has reinvigorated a molecular scientific approach including molecular genetics to gain an understanding of disease causation and progression. With a more precisely defined diffuse lung disease phenotype it is now possible to apply high throughput moderately fine mapping technologies to define genetic predisposition to disease and severity of disease. The more precise phenotype has also stimulated scientists to rethink concepts of pathogenesis particularly with regard to IPF and to re-explore the relative contributions of inflammation and fibrogenesis to this disease. This renaissance in scientific interest has stimulated the pharmaceutical industry into an unprecedented level of activity with regard to these diseases with investment in .